SRX Global Inc. (SRXH)
| Market Cap | 18.58M +209.0% |
| Revenue (ttm) | n/a |
| Net Income | -60,000 |
| EPS | n/a |
| Shares Out | 19.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $0.05 (5.25%) |
| Ex-Dividend Date | Jul 22, 2026 |
| Volume | 146,109 |
| Open | 0.9501 |
| Previous Close | 0.9410 |
| Day's Range | 0.9235 - 0.9637 |
| 52-Week Range | 0.7102 - 42.6120 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About SRXH
SRX Global Inc. operates an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. It leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across various sectors. The company is based in North Palm Beach, Florida.
Financial Performance
Financial StatementsNews
SRX Global Provides Update on Balance Sheet and Share Buyback
NORTH PALM BEACH, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value thr...
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership New platform t...
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-...
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX's proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 202...
SRX Global says adds investment in Onconetix
SRX Global Inc. (SRXH) announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (...
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ra...
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar
NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company
NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers The Debt investment is expected to accelerate development of CERo's lead therape...
SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results
Net Asset Value ("NAV") of $62.9 million , or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted...
SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET
NORTH PALM BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
SRX Global acquires stake in Vistagen
SRX Global (SRXH) announced that it has acquired a stake in Vistagen (VTGN). The company said it views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team…
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger
NORTH PALM BEACH, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
SRX Global Acquires Shares in Jersey Mike's $1 Billion Initial Public Offering
NORTH PALM BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
SRX Global Regains Full Compliance with NYSE American Listing Standards
Company Resolves Section 1003(a)(i) and (ii) Deficiencies; Compliance Indicator to Be Removed Company Resolves Section 1003(a)(i) and (ii) Deficiencies; Compliance Indicator to Be Removed
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
EMJX Shifted from “Stress” to “Mixed” for Bitcoin Company Files Updated Investor Presentation Outlining Performance and Strategy Management to Host Fireside Chat Today at 10:30am ET NORTH PALM BEACH, ...
SRX Global Management Team to Host Virtual Fireside Chat on July 14, 2026, and Issues Letter to Shareholders
Virtual Fireside Chat Scheduled for Tuesday, July 14, 2026, at 10:30 a.m. ET Virtual Fireside Chat Scheduled for Tuesday, July 14, 2026, at 10:30 a.m. ET
SRx Global Inc trading halted, news pending
11:41 EDT SRx Global Inc trading halted, news pending
SRx Global board authorizes stock repurchase plan up to 10M shares
SRX Global’s Board of Directors has authorized a share repurchase program under which the Company may repurchase up to 10M shares of its common stock or up to 50% of…
SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding
NORTH PALM BEACH, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value th...
